Newswire (Published: Tuesday, January 31, 2017, Received: Thursday, January 26, 2017, 3:38:15 PM CST)

Word Count: 457

New Prostate Cancer Findings from University of Athens Outlined (Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA > 4ng/mL, or with PIN biopsy result)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Athens, Greece, by NewsRx correspondents, research stated, "Data from animal, clinical and prevention studies support the role of androgens in prostate cancer growth, proliferation and progression. Results of serum based epidemiologic studies in humans, however, have been inconclusive."

Our news editors obtained a quote from the research from the University of Athens, "The present study aims to define whether serum testosterone can be used as a predictor of a positive second biopsy in males considered for re-biopsy. The study included 320 men who underwent a prostatic biopsy in our department from October 2011 until June 2012. Total testosterone, free testosterone, bioavailable testosterone and prostate pathology were evaluated in all cases. Patients undergoing a second biopsy were identified and biopsy results were statistically analyzed. Forty men (12.5%) were assessed with a second biopsy. The diagnosis of the second biopsy was High Grade Intraepithelial Neoplasia in 14 patients (35%) and Prostate Cancer in 12 patients (30%). The comparison of prostatic volume, total testosterone, sex hormone binding globulin, free testosterone, bioavailable testosterone and albumin showed that patients with cancer of the prostate had significantly greater levels of free testosterone (p=0.043) and bioavailable T (p=0.049). In our study, higher free testosterone and bioavailable testosterone levels were associated with a cancer diagnosis at re-biopsy."

According to the news editors, the research concluded: "Our results indicate a possible role for free and bioavailable testosterone in predicting the presence of prostate cancer in patients considered for re-biopsy."

For more information on this research see: Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA > 4ng/mL, or with PIN biopsy result. International Braz J Urol, 2016;42(5):925-931. International Braz J Urol can be contacted at: Brazilian Soc Urol, Rua Bambina, 153, Rio De Janeiro, 2251-050, Brazil (see also Oncology - Prostate Cancer).

The news editors report that additional information may be obtained by contacting A. Fiamegos, University of Athens, Sismanoglio Gen Hosp, Dept. of Urol 2, Athens, Greece. Additional authors for this research include J. Varkarakis, M. Kontraros, A. Karagiannis, M. Chrisofos, D. Barbalias and C. Deliveliotis.

Keywords for this news article include: Athens, Greece, Europe, Oncology, Epidemiology, Prostatic Neoplasms, Prostate Cancer, University of Athens.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


South America
Southern Europe
Rio de Janeiro


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer